$41.87
3.74% today
Nasdaq, Apr 04, 08:47 pm CET
ISIN
US92346J1088
Symbol
VCEL

Vericel Corporation Stock price

$43.49
-6.02 12.16% 1M
+2.14 5.18% 6M
-11.42 20.80% YTD
-7.84 15.27% 1Y
+4.24 10.80% 3Y
+34.99 411.65% 5Y
+39.80 1,078.59% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.82 1.85%
ISIN
US92346J1088
Symbol
VCEL
Sector

Key metrics

Market capitalization $2.18b
Enterprise Value $2.15b
P/E (TTM) P/E ratio 235.59
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.08
P/S ratio (TTM) P/S ratio 9.19
P/B ratio (TTM) P/B ratio 7.39
Revenue growth (TTM) Revenue growth 20.10%
Revenue (TTM) Revenue $237.22m
EBIT (operating result TTM) EBIT $4.52m
Free Cash Flow (TTM) Free Cash Flow $-5.81m
Cash position $126.74m
EPS (TTM) EPS $0.18
P/E forward 132.52
P/S forward 7.61
EV/Sales forward 7.51
Short interest 9.19%
Show more

Is Vericel Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Vericel Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Vericel Corporation forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Vericel Corporation forecast:

Buy
100%

Financial data from Vericel Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
237 237
20% 20%
100%
- Direct Costs 65 65
5% 5%
27%
172 172
27% 27%
73%
- Selling and Administrative Expenses 137 137
21% 21%
58%
- Research and Development Expense 25 25
18% 18%
10%
10 10
1,418% 1,418%
4%
- Depreciation and Amortization 5.50 5.50
23% 23%
2%
EBIT (Operating Income) EBIT 4.52 4.52
170% 170%
2%
Net Profit 10 10
426% 426%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Vericel Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vericel Corporation Stock News

Neutral
Investors Business Daily
about 3 hours ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
Seeking Alpha
30 days ago
Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest sign...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:
More Vericel Corporation News

Company Profile

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Head office United States
CEO Dominick Colangelo
Employees 357
Founded 1989
Website www.vcel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today